The EPA
Drug Initiative

Is the FDA ignoring heart risks from high triglycerides in the face of mounting evidence to the contrary?

The lives of millions of Americans are potentially at risk.

The EPA Drug Initiative (EPADI) urges the FDA to thoughtfully consider new and almost irrefutable proof that high triglycerides are a significant risk factor contributing to cardiovascular disease-related death and morbidity.

Recently, two independent studies were published in the prestigious New England Journal of Medicine (NEJM), both drawing the same conclusion: that reducing serum triglycerides to accepted, safe levels resulted in a 40% decrease in cardiovascular risk. These trial results are being universally hailed as groundbreaking, as they focus on people having a certain gene mutation, which elegantly eliminates all cardiovascular disease risk factors other than serum triglyceride levels. Both studies—from well-respected researchers—have caught the attention of the world, with the results being published by prominent news media including the New York Times and Forbes.

Read the Full Story

I am presently taking Vascepa because it does not raise LDL and it reduces inflammation. This is important because I have a stent in heart. I also take a statin but as you well know statins also reduce HDL's. From all the reading I've done regarding inflammation and it's effects on heart health, Vascepa in my opinion is a wonder drug. Pure EPA is without a doubt going to prove to be a very effective drug with no side effects. I'm looking forward to getting my blood work results. I'm certain they will be a pleasant surprise.

Edward Distefano
Watertown, Connecticut
Back To Top